Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children
Véronique Minard‐Colin(Inserm), Thomas G. Gross(Inserm), Aks Chiang(Hong Kong Adventist Hospital), Keith Wheatley(Cancer Research UK Clinical Trials Unit), Bernarda Kazanowska(Wroclaw Medical University), Rodney R. Miles(Inserm), Donald A. Barkauskas(University of Southern California), Sarah Alexander(BC Children's Hospital), Catherine Patte(Institut Gustave Roussy), Monika Csóka(Semmelweis University), Peter C. Adamson(University College London), Gilles Vassal(Université Paris-Saclay), Anne Uyttebroeck(Inserm), József Zsíros(Inserm), Marta Pillon(University of Padua), Anne Aupérin(Inserm), Rafael F. Delgado(Inserm), Catherine M. Bollard(Children's National), Andrew Wotherspoon(Université Libre de Bruxelles), G.A. Amos Burke(Inserm)
Cited by 308
Related Papers
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2010|1.9k
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|728
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge
|Journal of Clinical Oncology|2015|450